MacroGenics has been granted a patent for a Disease Antigen×CD3 (DA×CD3) Binding Molecule that can be used in the treatment of cancer and pathogen-associated diseases. The molecule comprises a CD3-Binding Domain and a Disease Antigen-Binding Domain, with specific amino acid sequences. The invention focuses on molecules with reduced affinity for CD3, which can mediate redirected killing of target cells while exhibiting lower levels of cytokine release. Pharmaceutical compositions containing these molecules are also included in the patent. GlobalData’s report on MacroGenics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MacroGenics, personalized cancer vaccines was a key innovation area identified from patents. MacroGenics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a da×cd3 binding molecule for cancer treatment
A recently granted patent (Publication Number: US11685781B2) describes a Disease Antigen×CD3 (DA×CD3) Binding Molecule that can be used for the treatment of hematological cancers. The molecule consists of a CD3-Binding Domain and a Disease Antigen-Binding Domain. The CD3-Binding Domain includes specific amino acid sequences, while the Disease Antigen-Binding Domain can bind to an epitope of CD123. The molecule can be in the form of a bispecific antibody, bispecific diabody, bispecific scFv, bispecific tetravalent tandem antibody, or a trivalent binding molecule.
The DA×CD3 Binding Molecule is composed of two polypeptide chains that are covalently bonded to each other. The first polypeptide chain includes a Domain 1 with sub-Domains 1A and 1B, which contain VL and VH Domains capable of binding to the epitopes of CD123 and CD3, respectively. The second polypeptide chain also includes a Domain 1 with sub-Domains 1A and 1B, but with the VL and VH Domains reversed. The VL Domain of the first polypeptide chain and the VH Domain of the second polypeptide chain form the Disease Antigen-Binding Domain, while the VH Domain of the first polypeptide chain and the VL Domain of the second polypeptide chain form the CD3-Binding Domain.
The patent also covers a pharmaceutical composition that includes the DA×CD3 Binding Molecule and a pharmaceutically acceptable carrier. This composition can be used for the treatment of hematological cancers by administering it to a subject in need. The patent further specifies the amino acid sequences of the Disease Antigen-Binding Domain and the CD3-Binding Domain, as well as the specific hematological cancers that can be targeted, including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), and various lymphomas.
The patent also includes methods for the treatment of hematological cancers using the pharmaceutical composition. The composition can be administered intravenously, either through infusion or at a specific dosage based on the subject's body weight. The administration can be done once a week, once every two weeks, or once a month.
Additionally, the patent describes a host cell that contains the polynucleotides encoding the polypeptide chains of the DA×CD3 Binding Molecule. This host cell can be used for the production of the molecule.
Overall, this patent provides a detailed description of a Disease Antigen×CD3 Binding Molecule and its potential applications in the treatment of hematological cancers.
To know more about GlobalData’s detailed insights on MacroGenics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
